AAAAAA
Results: 1-25/26
Authors:
ALATRAKCHI N
FARACE F
FRAU E
CARDE P
MUNCK JN
TRIEBEL F
Citation: N. Alatrakchi et al., T-CELL CLONAL EXPANSION IN PATIENTS WITH B-CELL LYMPHOPROLIFERATIVE DISORDERS, Journal of immunotherapy, 21(5), 1998, pp. 363-370
Authors:
TURSZ T
LECHEVALIER T
LECOSNE A
GAUTIER E
FARACE F
OPOION P
LAMY D
COURTNEY M
SQUIBAN P
Citation: T. Tursz et al., GENE-TRANSFER WITH RECOMBINANT ADENOVIRUS IN LUNG-CANCER - EXPERIENCEOF THE GUSTAVE-ROUSSY-INSTITUTE (IGR)-FRANCE, Annals of oncology, 9, 1998, pp. 69-69
Authors:
GAHERYSEGARD H
FARACE F
GODFRIN D
GASTON J
LENGAGNE R
TURSZ T
BOULANGER P
GUILLET JG
Citation: H. Gaherysegard et al., IMMUNE-RESPONSE TO RECOMBINANT CAPSID PROTEINS OF ADENOVIRUS IN HUMANS - ANTIFIBER AND ANTI-PENTON BASE ANTIBODIES HAVE A SYNERGISTIC EFFECT ON NEUTRALIZING ACTIVITY, Journal of virology, 72(3), 1998, pp. 2388-2397
Authors:
TURSZ T
LECESNE A
BALDEYROU P
GAUTIER E
OPOLON P
GRUNENWALD D
FARACE F
ZITVOGEL L
ESCUDIER B
SCHATZ C
COURTNEY M
LECHEVALIER T
Citation: T. Tursz et al., INTRATUMOR (IT) GENE-TRANSFER WITH RECOMBINANT ADENOVIRAL (RAD) VECTORS IN LUNG-CANCER (LC) PATIENTS (PTS) - THE INSTITUT-GUSTAVE-ROUSSY (IGR) EXPERIENCE, European journal of cancer, 33, 1997, pp. 602-602
Authors:
ESCUDIER B
LECESNE A
FARACE F
GAUTIER E
SAULNIER P
ZITVOGEL L
SCHATZ C
LAMY D
LECHEVALIER T
TURSZ T
Citation: B. Escudier et al., GENE-THERAPY WITH RECOMBINANT ADENOVIRUS IN LUNG-CANCER - FINAL RESULTS OF THE FRENCH PHASE-I STUDY, Cancer gene therapy, 4(6), 1997, pp. 35-35
Authors:
GAHERYSEGARD H
MOLINIERFRENKEL V
LEBOULAIRE C
SAULNIER P
OPOLON P
LENGAGNE R
GAUTIER E
LECESNE A
ZITVOGEL L
VENET A
SCHATZ C
COURTNEY M
LECHEVALIER T
TURSZ T
GUILLET JG
FARACE F
Citation: H. Gaherysegard et al., PHASE-I TRIAL OF RECOMBINANT ADENOVIRUS GENE-TRANSFER IN LUNG-CANCER - LONGITUDINAL-STUDY OF THE IMMUNE-RESPONSES TO TRANSGENE AND VIRAL PRODUCTS, The Journal of clinical investigation, 100(9), 1997, pp. 2218-2226
Authors:
FARACE F
ANGEVIN E
POULLION I
LEBOULLAIRE C
FERIR G
ELIAS D
ESCUDIER B
TRIEBEL F
Citation: F. Farace et al., T-CELL RECEPTOR CDR3 SIZE DISTRIBUTION ANALYSIS TO EVALUATE SPECIFIC T-CELL RESPONSE TO CANCER VACCINES, International journal of cancer, 71(6), 1997, pp. 972-977
Authors:
KUMAR A
FARACE F
GAUDIN C
TRIEBEL F
Citation: A. Kumar et al., CLONAL T-CELL EXPANSION INDUCED BY INTERLEUKIN-2 THERAPY IN BLOOD ANDTUMORS, The Journal of clinical investigation, 97(5), 1996, pp. 1219-1226
Authors:
ELIAS D
FARACE F
TRIEBEL F
HATTCHOUEL JM
PIGNON JP
LECESNE A
ROUGIER P
LASSER P
DUVILLARD P
ESCUDIER B
Citation: D. Elias et al., PHASE I-II RANDOMIZED STUDY ON PREHEPATECTOMY RECOMBINANT INTERLEUKIN-2 IMMUNOTHERAPY IN PATIENTS WITH METASTATIC CARCINOMA OF THE COLON AND RECTUM, Journal of the American College of Surgeons, 181(4), 1995, pp. 303-310
Authors:
ANGEVIN E
VALTEAUCOUANET D
FARACE F
DIETRICH PY
LECESNE A
TRIEBEL F
ESCUDIER B
Citation: E. Angevin et al., PHASE-I STUDY OF PROLONGED LOW-DOSE SUBCUTANEOUS RECOMBINANT INTERLEUKIN-2 (IL-2) IN PATIENTS WITH ADVANCED CANCER, Journal of immunotherapy with emphasis on tumor immunology, 18(3), 1995, pp. 188-195
Authors:
LECESNE A
VASSAL G
FARACE F
SPIELMANN M
LECHEVALIER T
TURSZ T
ESCUDIER B
Citation: A. Lecesne et al., CONCOMITANT INTERLEUKIN-2-DOXORUBICIN (ADR) SCHEDULE IN PATIENTS (PTS) WITH ADVANCED SOFT-TISSUE SARCOMAS (ASTS) - A PHARMACOKINETIC STUDY, European journal of cancer, 31A, 1995, pp. 586-586
Authors:
VALTEAUCOUANET D
RUBIE H
MERESSE V
FARACE F
BRANDELY M
HARTMANN O
Citation: D. Valteaucouanet et al., PHASE I-II STUDY OF INTERLEUKIN-2 AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN POORLY RESPONDING NEUROBLASTOMA, Bone marrow transplantation, 16(4), 1995, pp. 515-520
Authors:
FARACE F
ANGEVIN E
DIETRICH PY
LEBOULLAIRE C
VANDERPLANCKE J
ESCUDIER B
TRIEBEL F
Citation: F. Farace et al., LOW-DOSE IL-2 TREATMENT - ACTIVATION OF DISCRETE T-CELL AND NK-CELL SUBPOPULATIONS IN-VIVO, International journal of cancer, 62(5), 1995, pp. 523-528
Authors:
ESCUDIER B
FARACE F
THEODORE C
ANGEVIN E
COURT B
COUANET D
DIETRICH PY
CULINE S
PALLARDY M
HERCEND T
DROZ JP
Citation: B. Escudier et al., A NEW SCHEDULE OF INTERLEUKIN-2 FOR METASTATIC RENAL-CELL CARCINOMA -THE INSTITUT GUSTAVE-ROUSSY STUDY, Bulletin du cancer, 82(4), 1995, pp. 296-302
Authors:
ELIAS D
FARACE F
TRIEBEL F
HATTCHOUEL JM
LASSER P
ESCUDIER B
Citation: D. Elias et al., PHASE-I RANDOMIZED STUDY ON PREHEPATECTOMY RIL-2 IMMUNOTHERAPY IN PATIENTS WITH METASTATIC COLORECTAL-CANCER, British Journal of Surgery, 82, 1995, pp. 93-93
Authors:
ESCUDIER B
RAVAUD A
FABBRO M
DOUILLARD JY
NEGRIER S
CHEVREAU C
MIGNOT L
BAUME D
DORVAL T
VIGNAL F
FARACE F
MARANINCHI D
Citation: B. Escudier et al., HIGH-DOSE INTERLEUKIN-2 2 DAYS A WEEK FOR METASTATIC RENAL-CELL CARCINOMA - A FNCLCC MULTICENTER STUDY, Journal of immunotherapy with emphasis on tumor immunology, 16(4), 1994, pp. 306-312
Authors:
SAVELIEVA E
FARACE F
ANGEVIN E
ELIAS D
ESCUDIER B
DUVILLARD P
HERCEND T
TRIEBEL F
Citation: E. Savelieva et al., T-CELL RECEPTOR REPERTOIRE IN COLORECTAL ADENOCARCINOMA PATIENTS WITHHEPATIC METASTASES AND ITS CHANGES INDUCED BY PREOPERATIVE ADJUVANT INTERLEUKIN-2 THERAPY, Journal of immunotherapy with emphasis on tumor immunology, 16(1), 1994, pp. 66-76
Authors:
ESCUDIER B
FARACE F
ANGEVIN E
CHARPENTIER F
NITENBERG G
TRIEBEL F
HERCEND T
Citation: B. Escudier et al., IMMUNOTHERAPY WITH INTERLEUKIN-2 (IL2) AND LYMPHOKINE-ACTIVATED NATURAL-KILLER-CELLS - IMPROVEMENT OF CLINICAL-RESPONSES IN METASTATIC RENAL-CELL CARCINOMA PATIENTS PREVIOUSLY TREATED WITH IL2, European journal of cancer, 30A(8), 1994, pp. 1078-1083
Authors:
GENEVEE C
FARACE F
CHUNG V
DIU A
RAFFOUX C
CHARRON D
HERCEND T
TRIEBEL F
Citation: C. Genevee et al., INFLUENCE OF HUMAN-LEUKOCYTE ANTIGEN GENES ON TCR-V GENE SEGMENT FREQUENCIES, International immunology, 6(10), 1994, pp. 1497-1504
Authors:
FARACE F
ORLANDUCCI F
DIETRICH PY
GAUDIN C
ANGEVIN E
COURTIER MH
BAYLE C
HERCEND T
TRIEBEL F
Citation: F. Farace et al., T-CELL REPERTOIRE IN PATIENTS WITH B-CHRONIC LYMPHOCYTIC-LEUKEMIA - EVIDENCE FOR MULTIPLE IN-VIVO T-CELL CLONAL EXPANSIONS, The Journal of immunology, 153(9), 1994, pp. 4281-4290
Authors:
FARACE F
ANGEVIN E
VANDERPLANCKE J
ESCUDIER B
TRIEBEL F
Citation: F. Farace et al., THE DECREASED EXPRESSION OF CD3 XI-CHAINS IN CANCER-PATIENTS IS NOT REVERSED BY IL-2 ADMINISTRATION, International journal of cancer, 59(6), 1994, pp. 752-755
Authors:
FARACE F
PALLARDY M
ANGEVIN E
HERCEND T
ESCUDIER B
TRIEBEL F
Citation: F. Farace et al., METASTATIC RENAL-CELL CARCINOMA PATIENTS TREATED WITH INTERLEUKIN-2 OR INTERLEUKIN-2 PLUS INTERFERON-GAMMA - IMMUNOLOGICAL MONITORING, International journal of cancer, 57(6), 1994, pp. 814-821
Authors:
FARACE F
KREMER F
DIETRICH PY
GAUDIN C
ANGEVIN E
COURTIER MH
BAYLE C
HERCEND T
TRIEBEL F
Citation: F. Farace et al., ANALYSIS OF T-CELL REPERTOIRE IN B-CELL P ATIENTS - EVIDENCE FOR IN-VIVO T-CELL CLONAL EXPANSION, Bulletin du cancer, 81(10), 1994, pp. 897-899
Authors:
FARACE F
ANGEVIN E
ESCUDIER B
CAIGNARD A
DIETRICH PY
GENEVEE C
HERCEND T
TRIEBEL F
Citation: F. Farace et al., INFLUENCE OF INTERLEUKIN-2 ADMINISTRATION ON THE EXPRESSION OF T-CELLRECEPTOR V-GENE SEGMENTS IN PATIENTS WITH RENAL-CELL CARCINOMA, International journal of cancer, 54(5), 1993, pp. 741-747
Authors:
ANGEVIN E
FARACE F
GENEVEE C
HENRYAMAR M
CAIGNARD A
DIETRICH PY
ESCUDIER B
HERCEND T
TRIEBEL F
Citation: E. Angevin et al., ANALYSIS OF T-CELL-RECEPTOR VARIABLE GENE SEGMENT USAGE IN PERIPHERAL-BLOOD LYMPHOCYTES OF ADVANCED CANCER-PATIENTS, International journal of cancer, 54(1), 1993, pp. 60-67